May 04, 2026 4:01pm EDT FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 04, 2026 8:30am EDT FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Apr 30, 2026 5:55pm EDT FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
Apr 30, 2026 8:30am EDT FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
Apr 10, 2026 8:30am EDT FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
Mar 31, 2026 4:15pm EDT FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
Mar 25, 2026 4:30pm EDT FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement